News

Do you have any recent experiences of awe?

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

Awe and psychiatry: what is the connection for you?

Concussion is the most common type of traumatic brain injury. Unfortunately, many individuals that sustain a concussion are not seen in a medical setting. All health care providers should receive training in identifying the signs and symptoms of concussion in order to provide proper guidance and referral for specialized treatment.

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.

In this CME article, get a better understanding of bleeding risk associated with use of serotonin reuptake inhibitors (SRIs) and review research-informed literature on related bleeding complications in patients with cardiovascular and cerebrovascular disease.

Take a journey through the arts, and see the connections to psychiatry.

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

The development of the National Pediatric Boarding Consensus Panel guidelines attempts to provide hospitals suggestions for a safe, timely, and equitable standard of care for patients who are boarding.

“Are my other medications making my depression worse?” Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study.

From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.

What is new in research on psychedelics?

Here's how medical practitioners and researchers can influence AI reasoning and influence in the future of AI development and deployment.

Safety planning by peers is feasible and acceptable to patients, might result in decreased ED visits, and may represent a way of implementing safety plans in rural EDs.

"As society continues to grapple with the consequences of violent behaviors, increasing efforts to understand and mitigate the risks of such behaviors using evidence-based methods and tools will be essential."

Today, spread peace.

Today is World Alzheimer's Day!

The investigators noted fast, clinically meaningful, and sustained improvements in symptoms of depression and related functional impairment.

Welcome to the Emergency Psychiatry Special Report.

The drug’s developer announced that the FDA has made 2 clarifying revisions.

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.

An estimated 31% of physicians have been sued at some point in their careers. Here's what you need to know.

Is excess imprisonment a uniquely American problem?

Here’s what the historic case of the Genain quadruplets reveals about some deeper, uncomfortable truths about American society.

An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.

How can we ensure that diversity, equity, inclusion, and access are truly achieved in clinical trials industry-wide?

"For months she has dreamed in red..."

Awarding laughter… check out these past Ig Nobel Prize winners.

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.